Status:
COMPLETED
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
Up to 120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment. PURPOSE: Th...
Detailed Description
OBJECTIVES: * To screen serum specimens using a high throughput protein profiling platform that tests for the highest number of known biomarkers (detectable by antibodies) that could be predictors of...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of high-risk melanoma
- Receiving interferon alfa-2b therapy in arm II of clinical trial E-1694
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
January 14 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00897520
Start Date
January 14 2008
End Date
January 24 2010
Last Update
May 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.